New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec Presented at Society of Urologic Oncology Annual Meeting

In the study, nadofaragene firadenovec was administered directly into the patients bladder once every three months by a healthcare professional.